ArticleJournal of virology2001
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 142 citations in OpenAlex.
- Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.Journal of virology · 2019Article
- DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.The Journal of general virology · 2017Article
- Evaluation of the contribution of the transmembrane region to the ectodomain conformation of the human immunodeficiency virus (HIV-1) envelope glycoprotein.Virology journal · 2017Article
- Natural infection as a blueprint for rational HIV vaccine design.Human vaccines & immunotherapeutics · 2017Review
- Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers.Journal of virology · 2015Article
- Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env.Journal of virology · 2015Article
- Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.Nature communications · 2015Article
- A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.Journal of virology · 2015Article
- Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination.Bioconjugate chemistry · 2014Article
- Article
- A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140.Journal of virology · 2013Article
- Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.Journal of virology · 2013Article
- A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.PLoS pathogens · 2013Article
- Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate.Journal of translational medicine · 2013Article
- Article
- HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.Cold Spring Harbor perspectives in medicine · 2012Article
- Monoclonal antibody-based candidate therapeutics against HIV type 1.AIDS research and human retroviruses · 2012Review
- Article
- Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.The Journal of biological chemistry · 2012Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
The biologically active form of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein is oligomeric. We previously described a soluble HIV-1 IIIB Env protein, gp140, with a stable oligomeric structure composed of uncleaved gp120 linked to the ectodomain of gp41 (P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss, J. Virol. 68:3015-3026, 1994). Here we compared the antibody responses of rabbits to gp120 and gp140 that had been produced and purified in an identical manner. The gp140 antisera exhibited enhanced cross-reactivity with heterologous Env proteins as well as greater neutralization of HIV-1 compared to the gp120 antisera. To examine both immunogenicity and protective efficacy, we immunized rhesus macaques with oligomeric gp140. Strong neutralizing antibodies against a homologous virus and modest neutralization of heterologous laboratory-adapted isolates were elicited. No neutralization of primary isolates was observed. However, a substantial fraction of the neutralizing activity could not be blocked by a V3 loop peptide. After intravenous challenge with simian-HIV virus SHIV-HXB2, three of the four vaccinated macaques exhibited no evidence of virus replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.